- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05332743
Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair
A Multi-center, Single-arm Prospective Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hair loss is a common condition affecting both men and women that is more recently understood to be the result of multiple causes. Although it is generally a benign condition, hair loss can have a significant, detrimental impact on self-esteem, psychosocial functioning and the overall quality of life of affected individuals. It can also represent a substantial financial burden on individuals seeking treatment.
This is a 6-month, multi-center, single-arm prospective interventional study in adult female subjects who follow a plant-based diet with self-perceived hair thinning as confirmed by a dermatologist. The objective of this study is to assess the efficacy and safety of novel women's vegan supplement for hair growth.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Manhattan Beach, California, United States, 90266
- Ablon Skin Institute and Research Center
-
Sacramento, California, United States, 95815
- Integrative Skin Science and Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females of all Fitzpatrick skin, and hair types between 18-50 years of age with self-perceived thinning, confirmed by a dermatologist.
- Females leading a more plant-based lifestyle as of the last 3 months or longer according to the following categories: Vegetarian, Lacto-vegetarian, Ovo-Vegetarian, Lacto-ovo Vegetarian, Vegan, Raw Vegan, Pescatarian, Pollotarian, Flexitarian/Semi-Vegetarian
- Willing and able to adhere to the same dietary lifestyles for the duration of the study
- Able to understand and sign an informed consent agreement and photo release form approved by the Institutional Review Board
- General good health, as determined by the Investigator or qualified sub-investigator
- Willing and able to attend all study visits and comply with the test product daily instructions.
- Willing to maintain the same hair length, hairstyle, and coloring practices for the duration of the study. Subjects who have color-treated hair must have the color treatment performed at the same time interval prior to each visit.
- Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
- Willing and able to cooperate with the requirements of the study.
- Able to complete and understand the various rating instruments.
Exclusion Criteria:
- Individuals who are pregnant, planning a pregnancy, nursing, or within 1-year post-partum.
- Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
- Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
- Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation
- Individuals who have had a history of any acute or chronic medical or hair condition that could affect study results, such as a history of disordered eating
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), infection, cuts, and/ or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
- History of surgical correction of hair loss on the scalp (i.e., hair transplant).
- Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
- Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
- History of burning, flaking, itching, and stinging of the scalp.
- History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
- A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
- A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
- A known allergy to any of the ingredients in the investigational product.
- Utilization of low-level lasers for hair growth in the last three months.
- Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study or study results.
- Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day.
- Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nutraceutical Dietary Supplement
Nutraceutical Dietary Supplement capsules are comprised of primary and secondary ingredients, designed to restore hair health from the inside out.
In addition to the necessary vitamins, minerals, proteins to support the nutritional needs of hair.
|
Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health.
These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in terminal hair counts at Day 180 relative to baseline (Day 0)
Time Frame: 180 Days
|
Terminal Hair Counts
|
180 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in total, terminal and vellus and hair counts compared to baseline (Day 0)
Time Frame: 180 Days
|
All Hair Counts
|
180 Days
|
|
Change in Investigator Hair Quality Global Improvement Scale & Investigator Hair Growth Global Improvement Scale assessed by physician using standardized 2-D photographs compared to baseline.
Time Frame: 180 Days
|
Investigator Score using a 0 to 10 VAS scale
|
180 Days
|
|
Hair shedding pull test compared to baseline.
Time Frame: 180 Days
|
Hair Pull Test
|
180 Days
|
|
Subjective assessments of change in hair growth, appearance, and satisfaction measured with Subject Quality of Life Assessment
Time Frame: 180 Days
|
Subject self-assessments of satisfaction and perception using a 4-pt scale
|
180 Days
|
|
Compiled side effects, including all expected or unexpected side effects
Time Frame: All visits until 180 Days
|
All side effects occurring during the study, categorized by severity (Mild, moderate, severe) and relatedness to the study product or participation
|
All visits until 180 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NW-VW-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hair Thinning
-
DeNova ResearchTerminatedHair Loss | Hair ThinningUnited States
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
Nutraceutical Wellness Inc.TerminatedHair ThinningUnited States
-
Arbor Life LabsCompletedAndrogenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning HairUnited States
-
Arbor Life LabsCompletedAndrogenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning HairUnited States
-
Restore Biologics Holdings, Inc. dba XtresséEnrolling by invitationAlopecia | Hair Loss | Thinning Hair | Thin HairUnited States
-
NovoBliss Research Pvt LtdZYWIE VENTURES PRIVATE LIMITEDCompletedHair Thinning | Hair Brittle | Dry HairIndia
-
Hungkuang UniversitySchweitzer Biotech CompanyActive, not recruitingAlopecia | Hair Condition | Hair Loss | Hair Thinning | Sebum Production | Scalp Health | Hair HealthTaiwan
-
Revision SkincareDermicoCompleted
-
NovoBliss Research Pvt LtdBlossom Microbiotics LLCActive, not recruiting
Clinical Trials on Nutrafol Vegan Women's Hair Supplement
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
BrandiZoneCitruslabsCompletedHair Loss | Hair HealthUnited States
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
University of ExeterBeachbodyCompleted
-
Lacer S.A.CompletedEvaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair LossAndrogenetic Alopecia (AGA) | Chronic Telogen EffluviumItaly
-
Physicians Committee for Responsible MedicineCompleted
-
Physicians Committee for Responsible MedicineCompleted
-
University of ExeterBeachbodyCompletedMuscle RecoveryUnited Kingdom
-
Ablon Skin Institute Research CenterNutraceutical Wellness Inc.CompletedHair ThinningUnited States